This year alone, the American Cancer Society estimates almost two million new cancer cases will occur in the United States, and at least 25% of cases may be fatal. That’s why Paul de Figueiredo and his team at the University of Missouri are working to lower these numbers through the Synthetic Programmable bacteria for Immune-directed Killing in tumor Environments (SPIKEs) project.
This item is available in full to subscribers.
We have recently launched a new and improved website. To continue reading, you will need to either log into your subscriber account, or purchase a new subscription.
If you are a digital subscriber with an active subscription, then you already have an account here. Just reset your password if you've not yet logged in to your account on this new site.
If you are a current print subscriber, you can set up a free website account by clicking here.
Otherwise, click here to view your options for subscribing.
Please log in to continueNeed an account?
|
Other items that may interest you